Top Story

McClellan Suggests Adding Drug Spending To Alternative Pay Models

Former CMS Administrator Mark McClellan suggested that CMS consider including drug spending in alternative pay models, such as medical homes and accountable care organizations, to help curb rising specialty drug prices.

Latest News

The American Medical Association is urging Congress to make it easier for CMS to grant hardship exemptions following the delayed release of the Stage 2 meaningful use rule, as the group also pushes for future improvements to the electronic health records' meaningful use program.

Democratic presidential candidate Governor Martin O'Malley advocates for additional funding for FDA and the National Institutes of Health and expedited approval of breakthrough treatments, and also calls for the public release of clinical trial data, in his health care plan released on Tuesday (Nov. 24).

Democratic presidential candidate and former Maryland Gov. Martin O'Malley is targeting the 40-percent excise tax on high-cost health plans, high deductibles, the “family glitch” and the gap in coverage for potentially Medicaid-eligible residents in states that have not expanded Medicaid in a new 10-page health care policy blueprint released this week.

FDA lays out in newly released guidance documents why it will not mandate unique labeling for genetically engineered foods, and why it prefers manufacturers not use the terms genetically modified and genetically modified organism in any voluntary labeling.

FDA plans to collect 1,600 samples of cucumbers and hot peppers starting in November due to outbreaks related to each commodity and conduct whole genomic sequence testing on any samples that test positive for Salmonella, E. coli, and other contaminants.

Sens. Chuck Grassley (R-IA) and John McCain (R-AZ) are pressing HHS Secretary Sylvia Burwell to allow pharmacists, wholesale retailers and individuals to import cheaper Canadian versions of certain high-priced U.S. drugs.

A merger between two pharmaceutical heavyweights -- New York-based Pfizer and Dublin-based Allergan -- is making history as the largest inversion transaction, but is drawing scrutiny from Capitol Hill and the campaign trail for the same reason.

A bipartisan group of House lawmakers is asking the White House to include money to incorporate unique device identifiers (UDIs) into CMS claims forms in its fiscal year 2017 budget.